The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Drugs & Pharmaceuticals IPOs image Drugs & Pharmaceuticals IPOs » By The Online Investor Staff, updated Mon., Mar. 18, 10:54 PM
Recent initial public offerings in the Drugs & Pharmaceuticals IPOs category.

Slide #1. Syros Pharmaceuticals Initial Public Offering

Company: Syros Pharmaceuticals
Proposed Symbol: SYRS
Shares Offered: 4,000,000
Price Per Share: $12.50
Over-Allotment: 600,000
Description: Syros Pharmaceuticals today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $12.50 per share, before underwriting discounts and commissions. In addition, Syros has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Syros at the public offering price, less the underwriting discount and commissions, to cover over-allotments, if any. All of the shares are being offered by Syros Pharmaceuticals. The Company's shares are scheduled to begin trading on The NASDAQ Global Select Market on June 30, 2016 under the ticker symbol "SYRS." The offering is expected to close on July 6, 2016, subject to customary closing conditions.

IPOs: Syros Pharmaceuticals

List of Drugs & Pharmaceuticals IPOs in this Slideshow:
Company                                 Ticker    IPO Date
Regulus Therapeutics Inc.               RGLS      10/4/2012
Enanta Pharmaceuticals, Inc             ENTA      3/21/2013
Atossa Genetics, Inc.                   ATOS      11/8/2012
Zoetis                                  ZTS       
PTC Therapeutics, Inc.                  PTCT      
Prosensa Holding B.V.                   RNA       
Agios Pharmaceuticals, Inc.             AGIO      
Onconova Therapeutics, Inc.             ONTX      
Evoke Pharma, Inc.                      EVOK      
Karyopharm Therapeutics Inc.            KPTI      
MacroGenics, Inc                        MGNX      
Trevena, Inc.                           TRVN      
Xencor                                  XNCR      
ADMA Biologics                          ADMA      
Cara Therapeutics                       CARA      
Ultragenyx Pharmaceutical Inc.          RARE      
Intra-Cellular Therapies                ITCI      
uniQure B.V.                            QURE      
Revance Therapeutics                    RVNC      
Eagle Pharmaceuticals                   EGRX      
Akebia Therapeutics                     AKBA      
Phibro Animal Health Corporation        PAHC      
Agile Therapeutics, Inc.                AGRX      
MediWound Ltd                           MDWD      
Phibro Animal Health Corporation        PAHC      
Aldeyra Therapeutics                    ALDX      
Amphastar Pharmaceuticals, Inc.         AMPH      
Karyopharm Therapeutics Inc.            KPTI      
Affimed                                 AFMD      
Minerva Neurosciences, Inc.             NERV      
SAGE Therapeutics, Inc                  SAGE      
Ocular Therapeutix                      OCUL      
Catalent, Inc.                          CTLT      
Marinus Pharmaceuticals, Inc.           MRNS      
ProQR Therapeutics                      PRQR      
Dermira                                 DERM      
Ascendis Pharma A/S                     ASND      
Blueprint Medicines Corporation         BPMC      
Xbiotech                                XBIT      
Viking Therapeutics, Inc.               VKTX      
Collegium Pharmaceutical, Inc.          COLL      
Seres Therapeutics, Inc.                MCRB      
vTv Therapeutics Inc.                   VTVT      
Aclaris Therapeutics, Inc.              ACRS      
CytomX Therapeutics, Inc.               CTMX      
WAVE Life Sciences Ltd.                 WVE       
Mesoblast Limited                       MESO      
Corvus Pharmaceuticals, Inc.            CRVS      
Merus B.V.                              MRUS      
Clearside Biomedical, Inc.              CLSD      
Syros Pharmaceuticals                   SYRS      

March 18, 2024    10:54 PM Eastern

Drugs & Pharmaceuticals IPOs | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.